Global Breast Cancer Treatment Market Size Estimated to Generate Revenue USD 34.06 Billion by 2026: Facts & Factors
08 juin 2021 08h40 HE
|
Facts & Factors
New York, NY, June 08, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “Breast Cancer Treatment Market By Types (Invasive Lobular Carcinoma, Invasive Ductal...
Cancer Treatment Centers of America® Chicago Recognized for Achieving NAPBC Accreditation
11 nov. 2019 12h04 HE
|
Cancer Treatment Centers of America, Chicago
Zion, Ill., Nov. 11, 2019 (GLOBE NEWSWIRE) -- The National Accreditation Program for Breast Centers (NAPBC), a quality program of the American College of Surgeons (ACS), has granted three-year...
World-Renowned Pioneers in Oncoplastic Surgery Featured at Upcoming Global Summit in Las Vegas, January 2020
07 nov. 2019 12h47 HE
|
School of Oncoplastic Surgery
– Leading course teaches latest breast surgical oncology and plastic surgery techniques that dramatically improve patient outcomes – LAS VEGAS, Nov. 07, 2019 (GLOBE NEWSWIRE) -- The School of...
Genprex (GNPX) Featured in Audio Publication Discussing New Research on Breast Cancer Treatment
26 sept. 2019 08h30 HE
|
Genprex Inc Registered Shs
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – GNPX)">Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Gene Therapies with...
Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
23 sept. 2019 10h01 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the...
Sermonix Poster Presentation at 2019 ASCO Annual Meeting Demonstrates Promise for Lasofoxifene in Treating ER+ Metastatic Breast Cancer Patients With ESR1 Mutations
03 juin 2019 10h43 HE
|
Sermonix Pharmaceuticals LLC
Sermonix-sponsored University of Chicago preclinical investigation demonstrated: Lasofoxifene alone was significantly more effective than fulvestrant at inhibiting metastasis of both MCF7-Y537S and...
Sermonix to Present Poster on ‘Lasofoxifene as a Potential Treatment for ER+ Metastatic Breast Cancer’ at 2019 ASCO Annual Meeting
07 mai 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, May 07, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology...
Sermonix Pharmaceuticals Adds Three New Members to Its Board of Directors
23 avr. 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, April 23, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...
Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer
04 mars 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, March 04, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...
Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium
14 nov. 2018 10h00 HE
|
Sermonix Pharmaceuticals LLC
Posters to be displayed at Dec. 4-8 conference address introduction of Phase 2 study of investigational drug lasofoxifene, its effect on breast cancer and lung and liver metastasis in an in vivo...